Two women with the same tumour size and stage can need completely different treatments depending on what their cancer cells look like under a microscope. That difference comes down to subtype. Understanding which subtype a cancer is changes everything about how it is treated, how it behaves, and what the outlook looks like.
According to Dr. Garvit Chitkara, a leading Breast Cancer Surgeon in Mumbai,
“The first question after a breast cancer diagnosis is not just what stage it is. It is what subtype it is. The subtype tells us which treatments will work and which will not. A hormone receptor positive cancer responds to hormone therapy. A HER2 positive cancer needs targeted therapy. Triple-negative does not respond to either, so chemotherapy carries more weight. Getting this right at the start shapes the entire treatment plan.”
What do HR positive, HER2 positive, and triple-negative mean?
Each subtype is defined by which receptors are present on the cancer cells:
- HR positive (hormone receptor positive): The cancer cells have receptors for oestrogen, progesterone, or both. This is the most common subtype, accounting for roughly 70 percent of breast cancers. It tends to grow more slowly and responds well to hormone-blocking treatments like tamoxifen or aromatase inhibitors.
- HER2 positive: The cancer cells overexpress the HER2 protein, which drives rapid growth. It used to carry a poor prognosis. Targeted therapies like trastuzumab (Herceptin) have transformed outcomes significantly over the past two decades.
- Triple-negative: The cancer cells have none of the three receptors. No hormone therapy works. No HER2-targeted therapy works. Chemotherapy is the primary systemic treatment. Triple-negative cancers tend to be more aggressive and more likely to recur early, but they also respond well to chemotherapy when they respond at all.
- HR positive and HER2 positive: Some cancers are both. These get hormone therapy plus targeted HER2 therapy, making treatment more complex but outcomes generally favourable.
Surgery is part of treatment across all subtypes. What changes is what comes before or after it. The breast cancer surgery page covers the surgical options available regardless of subtype.
Could knowing your breast cancer subtype help predict which treatments are most likely to work for you?
How does treatment differ across subtypes?
The subtype does not change whether surgery is needed. It changes everything around it:
- HR positive treatment: Surgery plus radiation if breast conserved, followed by five to ten years of hormone therapy. Chemotherapy is added selectively based on tumour grade, size, and genomic test results like Oncotype DX.
- HER2 positive treatment: Chemotherapy is almost always given, combined with targeted HER2 therapy. Neoadjuvant chemotherapy before surgery is common to shrink the tumour and assess response. HER2-targeted therapy continues for a full year after surgery.
- Triple-negative treatment: Chemotherapy is the backbone, often given before surgery. Immunotherapy has recently been added for higher-risk cases. There is no maintenance therapy equivalent to hormone therapy, so the active treatment window is shorter but more intensive.
- Genomic testing for HR positive cancers: For early-stage HR positive HER2 negative cancers, genomic tests on the tumour tissue can quantify recurrence risk and guide whether chemotherapy adds meaningful benefit. This has spared many low-risk patients from unnecessary chemotherapy.
Treatment decisions also depend heavily on stage. For a detailed view of how subtype and stage interact in treatment planning, the stage 2 treatment blog is a useful reference.
Why Choose Dr Garvit Chitkara ?
Dr. Garvit Chitkara is Associate Director of Breast Surgical Oncology and Oncoplasty at Nanavati Max Institute of Cancer Care, Mumbai. With 17 years in breast surgical oncology and a background in molecular epidemiology and clinical research, he is experienced in managing all breast cancer subtypes within a multidisciplinary team. Every patient gets a treatment plan built around their specific subtype, stage, and personal circumstances. To book a consultation, call +91 91673 28325.
FAQ
Which breast cancer subtype has the best prognosis?
HR positive HER2 negative cancers detected early generally have the most favourable long-term outcomes. HER2 positive outcomes have improved dramatically with targeted therapy. Triple-negative is more aggressive but highly responsive to chemotherapy.
Can a cancer be both HR positive and triple-negative?
No. Triple-negative by definition means the cancer is negative for oestrogen receptors, progesterone receptors, and HER2. It cannot overlap with HR positive status.
Does subtype affect which surgery is recommended?
Not directly. Surgical decisions depend more on tumour size, location, and stage. Subtype influences what systemic treatment wraps around surgery rather than the surgical choice itself.
Is triple-negative breast cancer always more serious than other subtypes?
It tends to be more aggressive and has a higher early recurrence risk. But it also responds strongly to chemotherapy, and outcomes in patients who achieve a complete pathological response after neoadjuvant chemotherapy are excellent.
Disclaimer: This blog provides general information and should not be used as a substitute for personalised medical advice, diagnosis, or treatment.
